We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis, are also expected to be initiated soon, informed the company.
Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries announced a worldwide licensing agreement on the development and commercialisation of SCD-044.